Related Experiment Videos
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
E Steiner1, L Bertilsson, J Säwe
1Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.
Clinical Pharmacology and Therapeutics
|October 1, 1988
Summary
This study found that the debrisoquin hydroxylation phenotype is bimodally distributed in Swedish volunteers, with 5.4% identified as slow metabolizers. The debrisoquin phenotyping test demonstrated reproducibility and reliability for population studies.
Area of Science:
- Pharmacogenetics
- Drug Metabolism
- Population Genetics
Background:
- Debrisoquin hydroxylation is a well-established probe for cytochrome P450 2D6 (CYP2D6) activity.
- Genetic variations in CYP2D6 lead to distinct metabolic phenotypes, impacting drug efficacy and safety.
Purpose of the Study:
- To characterize the metabolic ratio (MR) distribution of debrisoquin in a healthy Swedish population.
- To assess the reproducibility and reliability of the debrisoquin phenotyping test.
- To compare the prevalence of slow debrisoquin hydroxylators across different ethnic groups.
Main Methods:
- Administration of a single oral dose of 10 mg debrisoquin to 757 healthy Swedish volunteers.
- Measurement of debrisoquin and 4-hydroxydebrisoquin in urine to calculate metabolic ratios (MRs).
- Evaluation of MR reproducibility with varying urine storage conditions and collection intervals; assessment of intraindividual repeatability.
Main Results:
- The metabolic ratios (MRs) exhibited a bimodal distribution, with 5.4% of subjects classified as slow debrisoquin hydroxylators (MR > 12.6).
- The MR was reproducible in urine stored at +8°C for 1 week and -20°C for 5 years.
- The debrisoquin phenotyping test showed high intraindividual repeatability.
- The frequency of the deficient hydroxylation allele in Swedes is similar to other white populations but differs significantly from Oriental groups.
Conclusions:
- The debrisoquin phenotyping test is a reliable method for determining CYP2D6 metabolic status in population studies.
- The prevalence of slow debrisoquin hydroxylators in the Swedish population aligns with other Caucasian groups.
- Further research with improved epidemiological techniques is needed to accurately compare prevalence across diverse ethnic groups.